

# Jean-Michel Lavoie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/164863/publications.pdf>

Version: 2024-02-01

17  
papers

377  
citations

1163117

8  
h-index

1125743

13  
g-index

17  
all docs

17  
docs citations

17  
times ranked

803  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. <i>Nature Cancer</i> , 2020, 1, 452-468.	13.2	103
2	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. <i>Nature Communications</i> , 2021, 12, 184.	12.8	85
3	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 202-212.	7.0	50
4	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. <i>European Urology</i> , 2021, 79, 16-19.	1.9	36
5	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 322-331.e2.	1.9	30
6	Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review. <i>Journal of Urology</i> , 2019, 202, 49-56.	0.4	24
7	Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis. <i>Prostate</i> , 2019, 79, 281-287.	2.3	15
8	Current Management of Disseminated Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2019, 46, 377-388.	1.8	10
9	18F FDG positron-emission tomography findings of gliomatosis peritonei: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2017, 20, 105-107.	0.6	9
10	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. <i>Oncologist</i> , 2021, 26, e1381-e1394.	3.7	8
11	Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 457-457.	1.6	3
12	Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC). <i>Journal of Clinical Oncology</i> , 2019, 37, 509-509.	1.6	2
13	Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .	1.0	2
14	Clinical characteristics and outcomes for young patients with advanced urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2020, 15, E123-E126.	0.6	0
15	Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis. <i>Investigational New Drugs</i> , 2020, 38, 1601-1604.	2.6	0
16	Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. <i>Urology Case Reports</i> , 2021, 39, 101762.	0.3	0
17	The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas. <i>Blood</i> , 2013, 122, 1804-1804.	1.4	0